StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Palvella Therapeutics's price to sales ratio was 12.7× on Jan 31, 2025, against 0.3× a year earlier. Over the last 5 years it ranged from 0.3× to 15.9×, with a median of 3.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 202512.7×+1.0
2024Dec 31, 202411.7×+11.4
2023Dec 29, 20230.3×−2.4
2022Dec 30, 20222.7×−8.2
2021Dec 31, 202110.9×+7.7
2020Dec 31, 20203.1×−2.1
2019Dec 31, 20195.3×+1.9
2018Dec 31, 20183.4×−30.9
2017Dec 29, 201734.3×+22.7
2016Dec 30, 201611.5×−5.4
2015Dec 31, 201517.0×–

More Palvella Therapeutics figures

See a number that looks wrong?